Innovent Biologics reports strong Q1 2025 revenue growth

Innovent Biologics Inc. (HKEX: 1801) reported strong financial performance for the first quarter of 2025, with total product revenue surpassing RMB2.4 billion, marking a year-on-year growth of over 40%. The company successfully launched four new products, including Dovbleron®, Limertinib, and Jaypirca® in oncology, and SYCUME® in general biomedicine. Innovent's established oncology treatments, such as TYVYT®, continued to drive growth, while new oncology products gained momentum. The company also noted the emergence of its general biomedicine products, particularly SINTBILO®, as new growth drivers. As of today, Innovent has 15 approved products, is awaiting regulatory review for three more, and continues to advance its extensive pipeline.